Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

879
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
879
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

764
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
764
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

235
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
235
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

198
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
198
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

668
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
668
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

396
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
396

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Postmyocardial Infarction Depression as a Modifiable Secondary Prevention Risk Factor.

Cardiology in review·2026
Same author

Coronary Artery Calcium as a Biological Staging Marker for Atherosclerosis: Aligning Preventive Therapies With Plaque Evolution.

Cardiology in review·2026
Same author

Beyond Diursesis: Rethinking Fluid and Sodium Strategies in Heart Failure.

Cardiology in review·2025
Same author

High-Density Lipoprotein Dysfunction and Atherosclerotic Cardiovascular Disease: From Quantity to Quality.

Cardiology in review·2025
Same author

Coenzyme Q10 in Heart Failure: Mechanisms and Therapeutic Potential.

Cardiology in review·2025
Same author

Survodutide: A Dual GLP-1/Glucagon Agonist Reshaping Cardiometabolic Care.

Cardiology in review·2025

Related Experiment Video

Updated: Jan 8, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

502

Albuminuria in Heart Failure: From Marker to Modifiable Target.

Amogh Jyothi Arun1, Shigeru Kaneki1, Madiha Baig1

  • 1From the School of Medicine, New York Medical College, Valhalla, NY.

Cardiology in Review
|December 22, 2025
PubMed
Summary

Albuminuria indicates heart failure (HF) severity and progression, reflecting endothelial dysfunction and systemic congestion. While treatments can lower albuminuria, its direct impact on HF outcomes requires further investigation.

Keywords:
albuminuriacardiorenal syndromeendothelial dysfunctionfinerenoneheart failureurinary albumin-to-creatinine ratio

More Related Videos

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.7K
A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
09:02

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

Published on: February 2, 2021

4.8K

Related Experiment Videos

Last Updated: Jan 8, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

502
Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.7K
A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
09:02

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

Published on: February 2, 2021

4.8K

Area of Science:

  • Cardiology
  • Nephrology
  • Vascular Biology

Background:

  • Albuminuria is increasingly recognized beyond a renal biomarker in heart failure (HF).
  • It signifies endothelial dysfunction, vascular injury, and systemic congestion, contributing to HF progression.
  • Oxidative and inflammatory injury drives albumin leakage via hemodynamic stress and renin-angiotensin-aldosterone system activation.

Purpose of the Study:

  • To review the role of albuminuria as an integrative indicator in heart failure.
  • To explore its association with disease severity, progression, and cardiovascular risk.
  • To discuss therapeutic implications and future research directions.

Main Methods:

  • Literature review of large studies (e.g., BIOlogy Study to TAilored Treatment in Chronic Heart Failure, FINerenone trial).
  • Analysis of correlations between albuminuria and markers of congestion, hospitalization, and mortality.
  • Examination of the impact of various therapies on albuminuria levels.

Main Results:

  • 40-50% of HF patients exhibit albuminuria, correlating with congestion markers.
  • Albuminuria independently predicts hospitalization and mortality in HF with reduced and preserved ejection fraction.
  • Low-grade albuminuria is linked to increased cardiovascular risk; changes in urinary albumin-to-creatinine ratio (uACR) track with outcomes.

Conclusions:

  • Albuminuria integrates renal, vascular, and hemodynamic risk in HF, serving as both a biomarker and potential therapeutic target.
  • Routine uACR measurement can enhance risk stratification and monitoring in HF.
  • Further research is needed to determine if reducing uACR improves HF outcomes.